Skip to main content
Midas Edge

IGC Pharma Inc

For the period ended Mar 31, 2025. Filed Jun 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jun 27, 2025

IGC$0.20-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENT OF STOCKHOLDERS’EQUITY

(in thousands)

Number of Common SharesCommon Stock and Additional Paid in Capital ($)Accumulated Deficit ($)Accumulated Other Comprehensive Loss ($)Total Stockholders’ Equity ($)
Balances as of April 1, 202353,077118,965(100,665)(3,389)14,911
Common stock-based compensation & expenses, net3,5341,917--1,917
Issuance of common stock through offering (net of expenses)10,5803,027--3,027
Share money received but not allotted-----
Cancellation/forfeiture of shares(500)----
Common stock subscribed-500--500
Other adjustments-----
Net loss--(13,000)-(13,000)
Foreign currency translation adjustments---(34)(34)
Balances as of March 31, 202466,691124,409(113,665)(3,423)7,321
Balances as of April 1, 202466,691124,409(113,665)(3,423)7,321
Common stock-based compensation & expenses, net-1,709--1,709
Issuance of common stock through offering (net of expenses)14,1874,252--4,252
Share money received but not allotted-200--200
Cancellation/forfeiture of shares-----
Common stock subscribed-----
Other adjustments--43(43)-
Net loss--(7,122)-(7,122)
Foreign currency translation adjustments---(30)(30)
Balances as of March 31, 202580,878130,570(120,744)(3,496)6,330
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.